UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235 Estimated average burden 3235-0287

0.5

11. Nature

hours per response.

7. Title and Amount 8. Price of 9. Number of 10.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Title of 2.

3. Transaction

3A. Deemed

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Type Responses) 1. Name and Address of Report Mazur Leonard L	ing Person *	2. Issuer Name and Citius Pharmaceu			~ ,	1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X. Director X. 10% Owner			
(Last) (Firs C/O CITIUS PHARMACE COMMERCE DRIVE, 1ST	3. Date of Earliest Tr 08/24-06:00/2017	,	Montl	n/Day/Ye	ar)	X Officer (give title below) Other (specify below) Executive Chairman				
CRANFORD, NJ 07016	et)	4. If Amendment, Da	ate Original	Filed	(Month/Day	/Year)	Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (Star	e) (Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	Date (Month/Day/Year) Execution Date, if (A) (Instr. 8) (Instr. 8)		(A) or D	Disposed of (D) , 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership		
Common Stock	08/24- 06:00/2017		P		11,000	A	\$ 2.68	3,337,730	D	
Reminder: Report on a separate	line for each class of securities	beneficially owned o	F	erso onta	ns who ined in	this for	m are	ne collection of information not required to respond unless the valid OMB control number.		1474 (9-02)

(e.g., puts, calls, warrants, options, convertible securities)

5. Number 6. Date Exercisable and

Derivativ Security (Instr. 3)	e Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Code		of Derivative Securities Acquired (A) or Disposed (D) (Instr. 3, and 5)	ve es d d of	Expiration Date (Month/Day/Year)		of Underlying Securities (Instr. 3 and 4)			Securities Beneficially Owned Following Reported Transaction(s)	Security: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warran to Purchas Commo	e \$ 4.125 n	08/24- 06:00/2017		P		11,000		02/08- 07:00/2018	08/08- 06:00/2022	Common Stock	11,000	\$ 0.54	11,000	D	
Warranto Purchas Commo	e \$ 6.15							(2)	06/12- 06:00/2019	Common Stock	19,614		19,614	D	
Warranto Purchas Commo	e \$ 9.9 n							<u>(2)</u>	09/30- 06:00/2019	Common Stock	3,171		3,171	D	
Warranto Purchas Commo	e \$ 9.9							<u>(2)</u>	01/08- 07:00/2020	Common Stock	4,984		4,984	D	
Warranto Purchas Commo	e \$ 7.5							(2)	08/18- 06:00/2020	Common Stock	35,211		35,211	D	
Warran to Purchas Commo Stock (2	e \$ 7.5 n							<u>(2)</u>	11/02- 07:00/2020	Common Stock	20,783		20,783	D	
Warran															

to Purchase Common Stock (2)	\$ 7.5			<u>(2)</u>	11/20- 07:00/2020	Common Stock	20,664	20,664	D	
Warrant to Purchase Common Stock (2)	\$ 7.5			(2)	01/08- 07:00/2021	Common Stock	13,679	13,679	D	
Warrant to Purchase Common Stock (2)	\$ 7.5			(2)	03/14- 07:00/2021	Common Stock	4,210	4,210	D	
Warrant to Purchase Common Stock (2)	\$ 6.15			(2)	03/15- 06:00/2021	Common Stock	18,106	18,106	D	
Warrant to Purchase Common Stock (3)	\$ 4.125			02/08- 07:00/2018	08/08- 06:00/2022	Common Stock	421,400	421,400	D	
Options to Purchase Common Stock (4)				<u>(4)</u>	09/12- 06:00/2024	Common Stock	220,000	220,000	D	

Reporting Owners

Dominica Communication / Addison	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Mazur Leonard L C/O CITIUS PHARMACEUTICALS, INC.	Х	Х	Executive Chairman					
11 COMMERCE DRIVE, 1ST FLOOR CRANFORD, NJ 07016	A	A	Executive Chamman					

Signatures

/s/ Erica B. Jackson, by power of attorney	08/28-06:00/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On August 24, 2017, the Report Person purchased a five-year warrant to purchase 11,000 shares of the Company's common stock at an exercise price of \$4.125 per share. The warrant is fully vested and exercisable six months from August 8, 2017.
- (2) The warrant is fully vested and exercisable immediately.
- (3) On August 8, 2017, the Reporting Person purchased a five-year warrant to purchase 421,400 shares of the Company's common stock at an exercise price of \$4.125 per share. The warrant is fully vested and exercisable six months from August 8, 2017.
- The option vests as to 40% of the shares of the Company's common stock on September 12, 2014 and 15% of the shares on each of September 12, 2015, March 12 and September 12, 2016 and September 12, 2017. The option was issued pursuant to the Company's 2014 Stock Incentive Plan.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it see} \ Instruction 6 \ for procedure.$

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of W. David Mannheim, Alexander M. Donaldson and Erica B. Jackson, and each of them acting alone, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% or more stockholder of Citius Pharmaceuticals, Inc. (the "Company"), Forms ID, 3, 4 and 5, and Update Passphrase Acknowledgement (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "1934 Act"), and the rules promulgated thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, 3, 4 and 5, and Update Passphrase Acknowledgement (and any amendments thereto) and to file timely such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the 1934 Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5, and Update Passphrase Acknowledgement with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned, in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of August 2017

/s/ Leonard L. Mazur Leonard L. Mazur